• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Apellis Pharmaceuticals

Izervay
Pharma

With sales turnaround, Astellas projects big growth for Izervay

After reporting a 15% sequential decline in sales of Izervay in the opening quarter of this year, Astellas has reversed the momentum for its GA drug.
Kevin Dunleavy Jul 10, 2025 4:30pm
empaveli

Sobi places $300M bet on Empaveli in partnership with Apellis

Jul 1, 2025 11:28am
Apellis

Apellis' Syfovre faces tough road ahead in GA market: analyst

May 14, 2025 11:10am
Apellis AstraZeneca FierceMadness drug ads

Apellis, AstraZeneca break down their #FierceMadness success

Apr 15, 2025 1:25pm
Fabhalta

Novartis' Fabhalta nod in C3G leaves room for rival Apellis

Mar 21, 2025 10:37am
Henry Winkler

Apellis expects sales of Syfovre to decline in Q1

Feb 28, 2025 3:05pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings